Skip to main content

and
Your search also matched 4 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Include preview-only content
  1. Article

    Open Access

    Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

    CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the be...

    Xavier Leleu, Cyrille Hulin, Jerome Lambert, Arthur Bobin, Aurore Perrot in Nature Medicine (2024)

  2. Article

    Open Access

    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

    GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (C...

    Francesc Bosch, Guy Cantin, Agostino Cortelezzi, Wolfgang Knauf, Mourad Tiab in Leukemia (2020)